MCID: DRM009
MIFTS: 39

Dermatomycosis

Categories: Skin diseases, Infectious diseases

Aliases & Classifications for Dermatomycosis

MalaCards integrated aliases for Dermatomycosis:

Name: Dermatomycosis 12 14
Dermatomycoses 41 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1563
ICD9CM 34 111 111.9
MeSH 41 D003881
UMLS 69 C0011630

Summaries for Dermatomycosis

Disease Ontology : 12 A cutaneous mycosis that results_in fungal infection located in skin or of its appendages, has material basis in Ascomycota fungi other than the dermatophytes.

MalaCards based summary : Dermatomycosis, also known as dermatomycoses, is related to eumycotic mycetoma and lobomycosis. An important gene associated with Dermatomycosis is RPS3 (Ribosomal Protein S3), and among its related pathways/superpathways is Amino sugar and nucleotide sugar metabolism. The drugs Ciclopirox and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin or of its appendages, skin and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 A dermatomycosis is a skin disease caused by a fungus. This excludes... more...

Related Diseases for Dermatomycosis

Graphical network of the top 20 diseases related to Dermatomycosis:



Diseases related to Dermatomycosis

Symptoms & Phenotypes for Dermatomycosis

GenomeRNAi Phenotypes related to Dermatomycosis according to GeneCards Suite gene sharing:

25 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.4 RPS3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.4 ZBTB22
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.4 ZBTB22
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.4 RPS3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.4 RPS3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.4 RPS3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.4 RPS3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.4 RPS3 ZBTB22
9 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.4 ZBTB22
10 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.4 ZBTB22
11 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.4 ZBTB22

Drugs & Therapeutics for Dermatomycosis

Drugs for Dermatomycosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciclopirox Approved, Investigational Phase 4,Phase 3,Phase 2 29342-05-0 2749
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
5
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
6
Caspofungin Approved Phase 4,Phase 3,Phase 2,Phase 1 162808-62-0, 179463-17-3 2826718 468682
7
Ketoconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65277-42-1 3823 47576
8
Bifonazole Approved, Investigational Phase 4,Phase 3,Phase 2 60628-96-8 2378
9
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 91161-71-6 1549008 5402
10
Naftifine Approved Phase 4,Phase 3,Phase 2,Phase 1 65472-88-0 47641 73342
11
Tavaborole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 174671-46-6
12
Itraconazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 84625-61-6 55283
13
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
14
Anidulafungin Approved, Investigational Phase 4,Phase 3,Phase 2 166663-25-8 166548
15
deoxycholic acid Approved Phase 4,Phase 3,Phase 2 83-44-3 222528
16
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 171228-49-2 147912
17
Micafungin Approved, Investigational Phase 4,Phase 3,Phase 2 235114-32-6 477468 3081921
18
Efinaconazole Approved Phase 4,Phase 3 164650-44-6
19
Omalizumab Approved, Investigational Phase 4 242138-07-4
20 Amorolfine Phase 4,Phase 3,Phase 2,Phase 1
21 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
26 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1
27 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
28 Hormones Phase 4,Phase 3,Phase 2,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
30 Keratolytic Agents Phase 4
31 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
32 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 Antacids Phase 4,Phase 1
34 Anti-Ulcer Agents Phase 4,Phase 1
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Proton pump inhibitors Phase 4,Phase 1
37 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
38 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Liposomal amphotericin B Phase 4,Phase 3,Phase 2
41 Echinocandins Phase 4,Phase 3,Phase 2,Phase 1
42 Hydroxyitraconazole Phase 4,Phase 2,Phase 3,Phase 1
43 Antitussive Agents Phase 4
44 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
45 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3,Phase 2
46 Anti-Allergic Agents Phase 4,Phase 2,Phase 3
47 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3
48 Antibodies Phase 4,Phase 1
49 Immunoglobulin E Phase 4
50 Immunoglobulins Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 327)

# Name Status NCT ID Phase Drugs
1 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
2 Aspergillus PCR Early Detection in High Risk Oncohematological Patients Unknown status NCT01742026 Phase 4
3 Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Unknown status NCT02394340 Phase 4 Omeprazole 40mg
4 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
5 Voriconazole for IPA in Chinese Patients With COPD Unknown status NCT02234739 Phase 4 Voriconazole
6 Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Unknown status NCT00986713 Phase 4 Amphotericin B
7 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
8 Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis Completed NCT02767947 Phase 4 Luliconazole Cream 1%;Vehicle Cream
9 An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis Completed NCT02466867 Phase 4 Naftin® Cream, 2% (younger pediatric cohort);Naftin® Cream, 2% (older pediatric cohort)
10 Pediatric Subjects With Tinea Corporis Completed NCT02227290 Phase 4 Naftin Cream;Placebo Cream
11 Ketoconazole Foam 2% for the Treatment of Versicolor Completed NCT00830388 Phase 4 Ketoconazole 2% Foam
12 A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Completed NCT00647907 Phase 4 Voriconazole
13 Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection Completed NCT00388167 Phase 4 Caspofungin
14 COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis Completed NCT00334412 Phase 4 Ambisome;caspofungin
15 Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients Completed NCT00177827 Phase 4
16 Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
17 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
18 Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
19 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
20 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl Nail Lacquer;Ciclopirox Nail Lacquer
21 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
22 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Completed NCT02321098 Phase 4 Loceryl Nail Lacquer;Loceryl Nail Lacquer;Loceryl Nail Lacquer follow up period
23 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
24 Topical Penlac Nail Lacquer for Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
25 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
26 Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis Completed NCT01259336 Phase 4 Itraconazole;treatment in cavitary pulmonary aspergillosis
27 A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
28 Amphotericin-B and Voriconazole for Pulmonary Blastomycosis Recruiting NCT02283905 Phase 4 amphotericin-B;voriconazole
29 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Recruiting NCT02812771 Phase 4 Efinaconazole
30 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
31 Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients Recruiting NCT03378479 Phase 4 SOC +Posaconazole 18 MG/ML (milligram/milliliter)
32 Study Evaluating the Effect of Jublia on Dermatophytomas Active, not recruiting NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
33 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Active, not recruiting NCT03110029 Phase 4 Efinaconazole 10% (Jublia)
34 Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Not yet recruiting NCT03280927 Phase 4 Jublia®
35 Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Terminated NCT01646580 Phase 4 ciclopirox
36 Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
37 Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis Terminated NCT02646774 Phase 4 Micafungin
38 Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene) Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
39 An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) Terminated NCT00787917 Phase 4 Omalizumab;Placebo;Itraconazole
40 A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
41 Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
42 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis Unknown status NCT01125644 Phase 3 SPK-843
43 Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Unknown status NCT01105013 Phase 3 Clotrimazole
44 TDT 067 Onychomycosis Study Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
45 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
46 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
47 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
48 Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Completed NCT01885156 Phase 3 Naftin 1% Cream;Placebo Cream
49 Topical Antifungal Treatment for Tinea Cruris Completed NCT01342315 Phase 3 33525;Placebo
50 Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101) Completed NCT02180165 Phase 3 Posaconazole;Voriconazole

Search NIH Clinical Center for Dermatomycosis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: dermatomycoses

Genetic Tests for Dermatomycosis

Anatomical Context for Dermatomycosis

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatomycosis:

18
Skin Or Of Its Appendages

MalaCards organs/tissues related to Dermatomycosis:

38
Skin, Testes, Lung, Bone, Myeloid, Thymus, Bone Marrow

Publications for Dermatomycosis

Articles related to Dermatomycosis:

(show top 50) (show all 104)
# Title Authors Year
1
<i>In Vitro</i> Antifungal Activity of Hexahydropyrimidine Derivatives against the Causative Agents of Dermatomycosis. ( 29226215 )
2017
2
Dermatomycosis due to Neoscytalidium spp. ( 27296436 )
2016
3
Dermatomycosis caused by Paranannizziopsis australasiensis in five tuatara (Sphenodon punctatus) and a coastal bearded dragon (Pogona barbata) in a zoological collection in New Zealand. ( 27074995 )
2016
4
SIXTEEN YEARS OF DERMATOMYCOSIS CAUSED BY Candida spp. IN THE METROPOLITAN AREA OF PORTO ALEGRE, SOUTHERN BRAZIL. ( 27007557 )
2016
5
Dermatomycosis in three central bearded dragons (Pogona vitticeps) associated with Nannizziopsis chlamydospora. ( 26951329 )
2016
6
Oral Antifungal Drugs in the Treatment of Dermatomycosis. ( 27251319 )
2016
7
Dermatomycosis frequency and localization sites. ( 25870481 )
2015
8
Dermatomycosis. ( 25231229 )
2014
9
Successfully treated dermatomycosis in California sea lions (Zalophus californianus). ( 23805567 )
2013
10
Species distribution and phospholipase activity of fungi isolated from children with dermatomycosis from child day care units in Natal, Brazil. ( 23279304 )
2013
11
Dermatomycosis in lower limbs of diabetic patients followed by podiatry consultation. ( 23147514 )
2013
12
Efficacy and safety of topical antifungals in the treatment of dermatomycosis: a systematic review. ( 22233283 )
2012
13
Prevalence of dermatomycosis in a Brazilian tertiary care hospital. ( 22936103 )
2012
14
In vitro antifungal activity of dihydroxyacetone against causative agents of dermatomycosis. ( 20936361 )
2011
15
Geotrichum candidum as etiological agent of horse dermatomycosis. ( 20970928 )
2011
16
Scopulariopsis brevicaulis as the cause of dermatomycosis. ( 20361882 )
2010
17
Dermatomycosis in a pet inland bearded dragon (Pogona vitticeps) caused by a Chrysosporium species related to Nannizziopsis vriesii. ( 19659541 )
2009
18
Dermatomycosis caused by common and rare fungi in Mumbai. ( 18797079 )
2008
19
Dermatomycosis in renal transplant recipients in Adana, Turkey. ( 18937667 )
2008
20
Dermatomycosis, hyperhydrosis, and mechanical injury to skin of the feet in Croatian soldiers during war in Croatia 1991-1992. ( 18751600 )
2008
21
Oral antifungal-exacerbated inflammatory flare-up reactions of dermatomycosis : case reports and review of the literature. ( 17007544 )
2006
22
Geomyces pannorum as a possible causative agent of dermatomycosis and onychomycosis in two patients. ( 16603097 )
2006
23
Trichophyton mentagrophytes var. quinckeanum as a cause of zoophilic dermatomycosis in a human family. ( 16642661 )
2005
24
In vitro susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China. ( 15504124 )
2004
25
Comparison of trypsin treatment method and standard laboratory technique for diagnosis of dermatomycosis. ( 15691144 )
2004
26
Epidemiology of dermatomycosis in the eastern Croatia--today and yesterday. ( 12955886 )
2003
27
Four cases of dermatomycosis: superficial cutaneous infection by Alternaria or Bipolaris. ( 14604084 )
2003
28
Diagnosing dermatomycosis in general practice. ( 10625138 )
1999
29
Continuous itraconazole treatment for onychomycosis and dermatomycosis: an overview of safety. ( 10523732 )
1999
30
Dermatomycosis in and around Aurangabad. ( 11127378 )
1999
31
Occurrence of dermatomycosis (ringworm) due to Trichophyton verrucosum in dairy calves and its spread to animal attendants. ( 10192093 )
1998
32
Dermatomycosis of the toe web caused by Curvularia lunata. ( 10030080 )
1998
33
Mycological aspects of dermatomycosis. ( 20948114 )
1996
34
Diagnosis and management of cases of suspected dermatomycosis in The Netherlands: influence of general practice based potassium hydroxide testing. ( 7612337 )
1995
35
Mycological aspects of dermatomycosis in Yavatmal (Maharashtra). ( 20952978 )
1995
36
Mycological aspects of dermatomycosis in Ludhiana. ( 8300168 )
1993
37
Response to treatment and recurrence of dermatomycosis in patients with diabetes. ( 8272485 )
1993
38
Double-blind comparative examination of ketoconazole 1% cream and clotrimazole 2% ointment in superficial dermatomycosis. ( 8278940 )
1993
39
Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. ( 2689013 )
1989
40
Dermatomycosis in dogs. ( 2710156 )
1989
41
Usefulness of ketoconazole (Nizoral) in the treatment of androgenization symptoms in women suffering concurrently from candidiasis or dermatomycosis. ( 3253961 )
1988
42
Fenticonazole cream once daily in dermatomycosis, a double-blind controlled trial versus bifonazole. ( 3049173 )
1988
43
Dermatomycosis in Udaipur region (Rajasthan). ( 3330981 )
1987
44
Dermatomycosis in southeast Rajasthan. ( 3878377 )
1985
45
Tinea versicolor dermatomycosis in the goat. ( 6735879 )
1984
46
Dermatomycosis in a pig and a ram. ( 6710841 )
1984
47
Patient noncompliance in dermatomycosis. Results of a survey among dermatologists and general practitioners and patients. ( 6526093 )
1984
48
The pros and cons of an oral treatment of dermatomycosis. ( 6098489 )
1984
49
Dermatomycosis in ranch foxes. ( 6511596 )
1984
50
Ketoconazole in the treatment of dermatomycosis in cats and dogs. ( 6314635 )
1983

Variations for Dermatomycosis

Expression for Dermatomycosis

Search GEO for disease gene expression data for Dermatomycosis.

Pathways for Dermatomycosis

GO Terms for Dermatomycosis

Molecular functions related to Dermatomycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase binding GO:0019900 8.96 CHIA RPS3
2 hydrolase activity, acting on glycosyl bonds GO:0016798 8.62 CHIA HEXA

Sources for Dermatomycosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....